pyrazinamide has been researched along with amg531 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Antipas, AS; Blumberg, LC; Brissette, WH; Brown, MF; Casavant, JM; Doty, JL; Driscoll, J; Harris, TM; Jones, CS; Li, Q; Linde, RG; Lira, PD; Marfat, A; McCurdy, SP; McElroy, E; Mitton-Fry, M; Munchhof, MJ; Reiter, LA; Ripp, SL; Shavnya, A; Thomasco, LM; Trevena, KA; Wolf-Gouveia, LA | 1 |
2 other study(ies) available for pyrazinamide and amg531
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
The identification of orally bioavailable thrombopoietin agonists.
Topics: Administration, Oral; Animals; Benzoates; Biological Availability; Caco-2 Cells; Humans; Hydrazines; Piperidines; Pyrazinamide; Pyrazoles; Pyrimidines; Rats; Receptors, Thrombopoietin | 2009 |